{"id":353610,"date":"2023-11-21T19:28:11","date_gmt":"2023-11-22T00:28:11","guid":{"rendered":"https:\/\/platohealth.ai\/gop-asks-cbo-to-address-concerns-about-the-ira\/"},"modified":"2023-11-22T19:00:15","modified_gmt":"2023-11-23T00:00:15","slug":"gop-asks-cbo-to-address-concerns-about-the-ira","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/gop-asks-cbo-to-address-concerns-about-the-ira\/","title":{"rendered":"GOP asks CBO to address concerns about the IRA","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

ARTICLE | Politics, Policy & Law<\/p>\n

\n
\n
\n

CBO asked to consider impacts on post-approval indications, delays in launching smaller indications, effects on generic, biosimilar competition\u00a0<\/h2>\n

\n By Steve Usdin, Washington Editor<\/span>\n<\/p>\n

November 22, 2023 12:28 AM UTC<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/span><\/span><\/div>\n

Republican members of Congress have asked the Congressional Budget Office a series of pointed questions about its analysis of the impacts of the Inflation Reduction Act\u2019s Medicare drug negotiation program. The questions reflect biopharma industry concerns that CBO\u2019s projections drastically understate the effects of the IRA on drug development. <\/span><\/p>\n

In a Nov. 20 letter<\/a>, Rep. Michael Burgess (R-Texas), chair of House Budget Committee\u2019s Health Care Task Force, and Jodey Arrington, chairman of the Budget Committee, asked if CBO is \u201ctracking trends in investments in early-stage drug development by venture capital firms following the passage of the IRA.\u201d…<\/p>\n